Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
Below is a list of the companies that produce the antiretrovirals we need in the patent pool.
Click on each company to see which drugs they produce and why we need them for the pool
Abbott Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson/Tibotec Pharmaceuticals
Merck & Co
Pfizer Inc.
Sequoia Pharmaceuticals Inc.
Indian Court Gives Boost to Access to Medicines As Latest Appeal By Bayer is Rejected
UNITAID Patent Pool: Innovative Initiative Designed to Boost Access to Medicines is Adopted
UNITAID Patent Pool: Key Developing Countries at Risk of Being Excluded
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
